Anisodamine

Phase 2Small molecule

SSun Yat-sen University

Anisodamine is one of 20 small molecule programs targeting Unresectable. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

UnresectableRecruiting

UnresectablePhase 2

Recruiting

Competition

Competitive Landscape

21 competitors in Unresectable

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

8 2

Tecentriq

Roche

Phase 3

3 3

Lenvima

Eisai

Phase 2

3 4

Vitrakvi

Bayer

Phase 2

1 5

Tagrisso

AstraZeneca

Phase 2

1 6

Tafinlar

Novartis

Phase 2

1 7

Camptosar

Pfizer

Phase 2

1 8

Zegfrovy

DDizal Pharmaceuticals

Phase 2

1 9

Xalkori

PPrism Pharmaceuticals

Phase 2

1 10

Ensacove

XXcovery Holdings, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Unresectable

NCT05727163

Clinical

Trials by Indication[1]

Nausea and vomiting1 trial

Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation

Completed·JJie Chen·Phase 1/2·NCT06045364·130 enrolled

Septic Shock1 trial

Anisodamine Critically Ill SeptIc Shock

Completed·JJinhua Central Hospital·Phase 1/2·NCT02442440·355 enrolled

Unresectable1 trial

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Recruiting·SSun Yat-sen University·Phase 2·NCT05727163·194 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Anisodamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anisodamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anisodamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

Anisodamine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Nausea and vomiting1 trial

Septic Shock1 trial

Unresectable1 trial

References

Drug Info

Quick Facts

Related News